CLOs on the Move

Innocrin Pharmaceuticals

www.innocrinpharma.com

 
Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

NextPhase Medical Devices

NextPhase Medical Device — Medical Device Contract Manufacturing Company–Your single source contract manufacturing company for medical device design, development, manufacturing, assembly, and complete supply chain management. We specialize in Sterile S...

ChemBridge

ChemBridge, Corp. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

LandsteinerScientific

LandsteinerScientific is a Chapel Hill, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

KC Pharmaceuticals

KC Pharmaceuticals is a Pomona, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BestCo

BestCo is a leading developer and manufacturer of innovative pharmaceutical dosage forms for the OTC (Over-the-Counter) Drug, Vitamin and Supplement marketplace.